Mentor Capital, Inc. - Thank You for Contacting Mentor Capital

Mentor Capital, Inc. and CI Companies

$10M Cancer Assets
3M Basic Shares

About Mentor Capital About MNTR Summary Data Management Team Professional Support Philosophy Ethics Corporate Governance Investor's Corner (Contract) Analysts' Coverage $5/Share - Sr. Securities Analyst Cancer Imm Index Information Visit Portfolio Companies

Trading Chart

Thank You!

Thank you for contacting Mentor Capital. Inc. We will do our best to get back to you as soon as possible.

The Mentor Capital Cancer Immunotherapy Index ^©

For Email Marketing you can trust

See Actual Cancer
Vaccine Results!

Home

Changing Assets & Acquisitions

Warrant Information

Chairman's Letters

◦	4,000% Increase in Four Months Triggers Early 2012 Annual Meeting
◦	Bringing It All Together To Win In The Cancer Fight (2011)
◦	Welcome To The Team Leading The Cancer Fight (2010)

Medicine, Science & The Economy

◦	Sunlight Explains Japan Radiation Risk

Press Releases

◦	Mentor Capital Cancer Immunotherapy Index Gains 47% During First Quarter
◦	Mentor Capital on High Growth Path with Planned $32 Million Health Care IT Investment
◦	Mentor Capital to Discuss Major Cancer Funding, Low PE and Warrant Call at April 29 Shareholder Meeting
◦	MNTR Earnings Exceed its Share Price for the Low PE Stock of this Socially Responsible Cancer Funding Company
◦	Mentor Capital Acquires 50 Percent of Brighter Day Health For $5M
◦	Mentor Capital Begins its 2012 Cancer Roll-up Strategy
◦	MNTR Acquires 30 Percent of European Cancer Vaccine for $4.71 Million
◦	Mentor Capital Adds to European Cancer Portfolio with AGI Biopharmaceuticals Melanoma Vaccine
◦	Mentor Capital Reports Mid-Year Profits for 2011
◦	Mentor Capital Initiates Discussions for Potential Merger
◦	Mentor Capital Seeks Funding Partners as Neutron Cancer Therapy Accelerates
◦	Cancer Immunotherapy Index Outpaces Biotechs
◦	Increased Chinese and International Visitors to Mentor Capital Site
◦	CEO Purchases an Additional 3.14% of MNTR Shares
◦	MNTR Drafts Five Cancer Funding Contracts for $40 Million
◦	MNTR Screens Cancer Companies For Investment At ASCO
◦	$125 Million for Socially Responsible Direct Cancer Funding
◦	Advaxis Added To Cancer Immunotherapy Index
◦	MNTR In Discussion With Breast Cancer Immunotherapy Company
◦	Nobel Laureate Reinforces the Mentor Capital Strategy to Fund Only Leading-edge Cancer Science
◦	Mentor Capital to Expand Funding Bridge Over Cancer Development Gap
◦	Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval
◦	MNTR Sees Shift To Public Acceptance
◦	Cancer Index at New High with 12 Yr Exclusive Period in Health Bill
◦	Provectus Pharmaceuticals (PVCT) added to Cancer Immunotherapy Index
◦	MNTR Invests in 10 Cancer Index Companies
◦	MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund
◦	2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR
◦	MNTR Presents in NYC
◦	QI Announces MNTR
◦	MNTR Calls $3 Million Tranche
◦	MNTR Initiates Trading

Cancer Resources

Information For Brokers

Shareholder Updates

FAQ

Safe Harbor Statement Site Map